Novo Nordisk Reduces Prices for Ozempic and Wegovy Amid Efforts to Expand Access
Just the facts

Novo Nordisk Reduces Prices for Ozempic and Wegovy Amid Efforts to Expand Access

Summary

Novo Nordisk has announced significant price reductions for its GLP-1 medications, Ozempic and Wegovy, aiming to enhance affordability and accessibility for patients without insurance coverage.

Novo Nordisk has announced significant price reductions for its GLP-1 medications, Ozempic and Wegovy, aiming to enhance affordability and accessibility for patients without insurance coverage. Effective immediately, the monthly cost for self-paying patients has been reduced from $499 to $349. Additionally, new patients can access an introductory offer of $199 per month for the first two months, applicable to the initial doses of both medications.

These pricing adjustments are part of Novo Nordisk's broader strategy to expand access to FDA-approved semaglutide medicines across various channels, including partnerships with telehealth providers and major retailers. The company has also collaborated with Costco to offer these medications at the discounted rate of $499 per month to its members.

The price reductions align with a recent agreement between the Trump administration and pharmaceutical companies, including Novo Nordisk and Eli Lilly, to lower the cost of GLP-1 drugs for Medicare and Medicaid beneficiaries. Under this agreement, these medications will be available for as low as $50 per month for eligible patients, with broader coverage expected to commence in 2026.

Despite these efforts, healthcare professionals express concerns that the treatments may remain unaffordable for some uninsured patients. Experts emphasize that insurance coverage, not just price cuts, is critical for access.

Novo Nordisk's initiatives reflect a growing trend among pharmaceutical companies to make weight-loss medications more accessible amid increasing demand and competition in the market.

Source

NBC News

Keep reading — for free

Create a free account to follow the news. No card required.